Literature DB >> 23953998

Review of the state of renal nerve ablation for patients with severe and resistant hypertension.

Vinay Gulati1, William B White2.   

Abstract

Through modulation of renin secretion, glomerular filtration rate, and renal absorption of sodium, the sympathetic innervation of the kidneys plays an important role in the pathogenesis of hypertension. Renal nerve ablation technology is being developed for treatment of drug-treatment-resistant hypertension worldwide. Preliminary research with the use of radiofrequency-based renal denervation systems have demonstrated encouraging results with significant reduction of blood pressure in patients inadequately controlled despite nearly maximal drug therapy regimens. From work done thus far, the renal denervation procedure has not been associated with serious adverse effects. Long-term efficacy and safety still needs to be established for renal nerve ablation. This review focuses on the impact of the renal sympathetic system on blood pressure regulation, the clinical rationale for renal nerve ablation in severe and drug-treatment-resistant hypertension, and current evidence from the more advanced renal denervation devices.
Copyright © 2013 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Resistant hypertension; renal nerve ablation; sympathetic nervous system

Mesh:

Year:  2013        PMID: 23953998      PMCID: PMC3855181          DOI: 10.1016/j.jash.2013.07.003

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  52 in total

1.  Hypertension and associated cardiovascular disease; comparison of male and female mortality rates and their influence on selection of therapy.

Authors:  R H SMITHWICK; R D BUSH; D KINSEY; G P WHITELAW
Journal:  J Am Med Assoc       Date:  1956-03-24

2.  Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter.

Authors:  Dirk Prochnau; Norma Lucas; Helmut Kuehnert; Hans R Figulla; Ralf Surber
Journal:  EuroIntervention       Date:  2012-01       Impact factor: 6.534

3.  Renal denervation in moderate to severe CKD.

Authors:  Dagmara Hering; Felix Mahfoud; Antony S Walton; Henry Krum; Gavin W Lambert; Elisabeth A Lambert; Paul A Sobotka; Michael Böhm; Bodo Cremers; Murray D Esler; Markus P Schlaich
Journal:  J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 10.121

Review 4.  Functional role of renal afferents.

Authors:  A Stella; A Zanchetti
Journal:  Physiol Rev       Date:  1991-07       Impact factor: 37.312

5.  Effect of sympathectomy on blood pressure in hypertension; a review of 13 years' experience of the Massachusetts General Hospital.

Authors:  K A EVELYN; F ALEXANDER; S R COOPER
Journal:  J Am Med Assoc       Date:  1949-06-18

6.  Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension.

Authors:  Mathias C Brandt; Sara Reda; Felix Mahfoud; Matthias Lenski; Michael Böhm; Uta C Hoppe
Journal:  J Am Coll Cardiol       Date:  2012-10-10       Impact factor: 24.094

7.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.

Authors:  G Ligtenberg; P J Blankestijn; P L Oey; I H Klein; L T Dijkhorst-Oei; F Boomsma; G H Wieneke; A C van Huffelen; H A Koomans
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

8.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

9.  Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.

Authors:  Felix Mahfoud; Christian Ukena; Roland E Schmieder; Bodo Cremers; Lars C Rump; Oliver Vonend; Joachim Weil; Martin Schmidt; Uta C Hoppe; Thomas Zeller; Axel Bauer; Christian Ott; Erwin Blessing; Paul A Sobotka; Henry Krum; Markus Schlaich; Murray Esler; Michael Böhm
Journal:  Circulation       Date:  2013-06-18       Impact factor: 29.690

10.  Improved heart rate dynamics in patients undergoing percutaneous renal denervation.

Authors:  Frank Himmel; Joachim Weil; Michael Reppel; Kai Mortensen; Klaas Franzen; Leidinger Ansgar; Heribert Schunkert; Frank Bode
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-31       Impact factor: 3.738

View more
  6 in total

1.  Renal denervation in the treatment of resistant arterial hypertension.

Authors:  Thomas Lambert; Wilhelm Schützenberger; Clemens Steinwender
Journal:  Wien Med Wochenschr       Date:  2014-11-14

2.  Norepinephrine deficiency with normal blood pressure control in congenital insensitivity to pain with anhidrosis.

Authors:  Lucy Norcliffe-Kaufmann; Stuart D Katz; Felicia Axelrod; Horacio Kaufmann
Journal:  Ann Neurol       Date:  2015-03-13       Impact factor: 10.422

Review 3.  Controversies Surrounding Renal Denervation: Lessons Learned From Real-World Experience in Two United Kingdom Centers.

Authors:  Amy E Burchell; Kenneth Chan; Laura E K Ratcliffe; Emma C Hart; Manish Saxena; David J Collier; Ajay K Jain; Anthony Mathur; Charles J Knight; Mark J Caulfield; Julian F R Paton; Angus K Nightingale; Melvin D Lobo; Andreas Baumbach
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-02-09       Impact factor: 3.738

4.  Hypertension guidances published in 2013: a busy year with more to follow.

Authors:  J Rick Turner; Snehal Kothari
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-03-19       Impact factor: 3.738

5.  Meta-methodology: conducting and reporting meta-analyses.

Authors:  J Rick Turner; Todd A Durham
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02       Impact factor: 3.738

Review 6.  Proteinuria and its relation to cardiovascular disease.

Authors:  Gemma Currie; Christian Delles
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.